Skip to main content
SpringerLink
Log in

Proliferative Vitreoretinopathy

  • Living reference work entry
  • First Online:
Albert and Jakobiec's Principles and Practice of Ophthalmology

  • 72 Accesses

Abstract

Proliferative vitreoretinopathy (PVR) is a clinical syndrome associated with proliferation of cells in the vitreous cavity and on the retinal surface leading to tractional forces on the retina. PVR is the most common cause of re-detachment after retinal detachment surgery and remains a difficult disease to manage and treat. The pathophysiology of PVR formation is complex and remains incompletely understood. Clinically, PVR can be classified according to severity, location, and extent. Current management of PVR is largely surgical including vitrectomy, membrane peeling, scleral buckling, and intraocular tamponade. While there are agents currently under investigation, there remains limited medical adjuvants in PVR treatment and prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Hilton G, Machemer R, Michels R, Okun E, Schepens C, Schwartz A. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90(2):121–5.

    Article  Google Scholar 

  2. Idrees S, Sridhar J, Kuriyan AE. Proliferative vitreoretinopathy: a review. Int Ophthalmol Clin. 2019;59(1):221–40. https://doi.org/10.1097/iio.0000000000000258.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S. Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res. 2016;51:125–55. https://doi.org/10.1016/j.preteyeres.2015.07.005.

    Article  PubMed  Google Scholar 

  4. Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol. 2004;137(6):1105–15. https://doi.org/10.1016/j.ajo.2004.02.008.

    Article  PubMed  Google Scholar 

  5. Speicher MA, Fu A, Martin JP. Primary vitrectomy alone for repair of retinal detachments following cataract surgery. Retina (Philadelphia, Pa). 2000;20(5):459–64.

    Article  CAS  Google Scholar 

  6. Duquesne N, Bonnet M, Adeleine P. Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol. 1996;234(11):677–82.

    Article  CAS  PubMed  Google Scholar 

  7. Greven CM, Sanders RJ, Brown GC, et al. Pseudophakic retinal detachments: anatomic and visual results. Ophthalmology. 1992;99(2):257–62.

    Article  CAS  PubMed  Google Scholar 

  8. Girard P, Mimoun G, Karpouzas I, Montefiore G. Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina (Philadelphia, Pa). 1994;14(5):417–24.

    Article  CAS  Google Scholar 

  9. Gartry D, Chignell A, Franks W, Wong D. Pars plana vitrectomy for the treatment of rhegmatogenous retinal detachment uncomplicated by advanced proliferative vitreoretinopathy. Br J Ophthalmol. 1993;77(4):199–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bonnet M, Fleury J, Guenoun S, Yaniali A, Dumas C, Hajjar C. Cryopexy in primary rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol. 1996;234(12):739–43.

    Article  CAS  PubMed  Google Scholar 

  11. Heimann H, Bornfeld N, Friedrichs W, et al. Primary vitrectomy without scleral buckling for rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol. 1996;234(9):561–8.

    Article  CAS  PubMed  Google Scholar 

  12. Lindsell LB, Sisk RA, Miller DM, et al. Comparison of outcomes: scleral buckling and pars plana vitrectomy versus vitrectomy alone for primary repair of rhegmatogenous retinal detachment. Clin Ophthalmol (Auckland, NZ). 2017;11:47–54. https://doi.org/10.2147/opth.S112190.

    Article  Google Scholar 

  13. Oellers P, Stinnett S, Hahn P. Valved versus nonvalved cannula small-gauge pars plana vitrectomy for repair of retinal detachments with Grade C proliferative vitreoretinopathy. Clin Ophthalmol (Auckland, NZ). 2016;10:1001–6. https://doi.org/10.2147/opth.S104901.

    Article  CAS  Google Scholar 

  14. Nagasaki H, Shinagawa K, Mochizuki M. Risk factors for proliferative vitreoretinopathy. Prog Retin Eye Res. 1998;17(1):77–98.

    Article  CAS  PubMed  Google Scholar 

  15. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21(1):127–44.

    Article  PubMed  Google Scholar 

  16. Mietz H, Heimann K. Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease. Br J Ophthalmol. 1995;79(10):874–7. https://doi.org/10.1136/bjo.79.10.874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Laqua H, Machemer R. Glial cell proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol. 1975;80(4):602–18.

    Article  CAS  PubMed  Google Scholar 

  18. Machemer R, Laqua H. Pigment epithelium proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol. 1975;80(1):1–23.

    Article  CAS  PubMed  Google Scholar 

  19. Kim IK, Arroyo JG. Mechanisms in proliferative vitreoretinopathy. Ophthalmol Clin N Am. 2002;15(1):81–6.

    Article  Google Scholar 

  20. Sadaka A, Giuliari GP. Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol (Auckland, NZ). 2012;6:1325–33. https://doi.org/10.2147/opth.S27896.

    Article  Google Scholar 

  21. Constable I, Nagpal M. Chapter 111: Proliferative vitreoretinopathy. In: Schachat A, Wilkinson C, Hinton D, Sadda S, Wiedemann P, editors. Ryan’s Retina. 6th ed. Elsevier; 2017.

    Google Scholar 

  22. Johnson N, Foulds W. Observations on the retinal pigment epithelium and retinal macrophages in experimental retinal detachment. Br J Ophthalmol. 1977;61(9):564–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Singh AK, Michels RG, Glaser BM. Scleral indentation following cryotherapy and repeat cryotherapy enhance release of viable retinal pigment epithelial cells. Retina (Philadelphia, Pa). 1986;6(3):176–8.

    Article  CAS  Google Scholar 

  24. Gilbert C, Hiscott P, Unger W, Grierson I, McLeod D. Inflammation and the formation of epiretinal membranes. Eye. 1988;2(S1):S140.

    Article  PubMed  Google Scholar 

  25. Lean J, Nooril S, Crisp A, et al. Response of the RPE monolayer to retinal hole formation. In: Heimann K, Wiedemann P, editors. Response of the RPE monolayer to retinal hole formation. Kaden; 1989.

    Google Scholar 

  26. Chen Z, Shao Y, Li X. The roles of signaling pathways in epithelial-to-mesenchymal transition of PVR. Mol Vis. 2015;21:706–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Stern J, Temple S. Retinal pigment epithelial cell proliferation. Exp Biol Med (Maywood, NJ). 2015;240(8):1079–86. https://doi.org/10.1177/1535370215587530.

    Article  CAS  Google Scholar 

  28. Peters M, Burke J, Clowry M, Abrams G, Williams G. Development of traction retinal detachments following intravitreal injections of retinal Muller and pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 1986;224(6):554–63.

    Article  CAS  PubMed  Google Scholar 

  29. McLeod D, Hiscott P, Grierson I. Age-related cellular proliferation at the vitreoretinal juncture. Eye. 1987;1(2):263.

    Article  PubMed  Google Scholar 

  30. Foos RY, Gloor BP. Vitreoretinal juncture; healing of experimental wounds. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1975;196(3):213–30.

    Article  CAS  PubMed  Google Scholar 

  31. Rowen SL, Glaser BM. Retinal pigment epithelial cells release a chemoattractant for astrocytes. Arch Ophthalmol. 1985;103(5):704–7.

    Article  CAS  PubMed  Google Scholar 

  32. Newsome DA, Rodrigues MM, Machemer R. Human massive periretinal proliferation: in vitro characteristics of cellular components. Arch Ophthalmol. 1981;99(5):873–80.

    Article  CAS  PubMed  Google Scholar 

  33. Cleary PE, Ryan SJ. Histology of wound, vitreous, and retina in experimental posterior penetrating eye injury in the rhesus monkey. Am J Ophthalmol. 1979;88(2):221–31.

    Article  CAS  PubMed  Google Scholar 

  34. Grierson I, Forrester JV. Vitreous haemorrhage and vitreal membranes. Trans Ophthalmol Soc U K. 1980;100(Pt 1):140–50.

    CAS  PubMed  Google Scholar 

  35. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell. 1986;46(2):155–69.

    Article  CAS  PubMed  Google Scholar 

  36. Jerdan JA, Pepose JS, Michels RG, et al. Proliferative vitreoretinopathy membranes: an immunohistochemical study. Ophthalmology. 1989;96(6):801–10.

    Article  CAS  PubMed  Google Scholar 

  37. Campochiaro PA, Jerdon J, Glaser BM. The extracellular matrix of human retinal pigment epithelial cells in vivo and its synthesis in vitro. Invest Ophthalmol Vis Sci. 1986;27(11):1615–21.

    CAS  PubMed  Google Scholar 

  38. Burke JM, Kower HS. Collagen synthesis by rabbit neural retina in vitro and in vivo. Exp Eye Res. 1980;31(2):213–26.

    Article  CAS  PubMed  Google Scholar 

  39. Bryan JA, Campochiaro PA. A retinal pigment epithelial cell-derived growth factor (s). Arch Ophthalmol. 1986;104(3):422–5.

    Article  CAS  PubMed  Google Scholar 

  40. Burke J, Foster S. Induction of DNA synthesis by co-culture of retinal glia and pigment epithelium. Invest Ophthalmol Vis Sci. 1985;26(5):636–42.

    CAS  PubMed  Google Scholar 

  41. Burke JM, Twining SS. Vitreous macrophage elicitation: generation of stimulants for pigment epithelium in vitro. Invest Ophthalmol Vis Sci. 1987;28(7):1100–7.

    CAS  PubMed  Google Scholar 

  42. Campochiaro PA, Glaser BM. A retina-derived stimulator (s) of retinal pigment epithelial cell and astrocyte proliferation. Exp Eye Res. 1986;43(3):449–57.

    Article  CAS  PubMed  Google Scholar 

  43. Hackett SF, Conway BP, Campochiaro PA. Subretinal fluid stimulation of retinal pigment epithelial cell migration and proliferation is dependent on certain features of the detachment or its treatment. Arch Ophthalmol. 1989;107(3):391–4.

    Article  CAS  PubMed  Google Scholar 

  44. Harvey A, Roberge F, Hjelmeland LM. Chemotaxis of rat retinal glia to growth factors found in repairing wounds. Invest Ophthalmol Vis Sci. 1987;28(7):1092–9.

    CAS  PubMed  Google Scholar 

  45. Campochiaro PA, Sugg R, Grotendorst G, Hjelmeland LM. Retinal pigment epithelial cells produce PDGF-like proteins and secrete them into their media. Exp Eye Res. 1989;49(2):217–27.

    Article  CAS  PubMed  Google Scholar 

  46. Connor T. RPE cells synthesize and release transforming growth factor-beta, a modulator of endothelial cell growth and wound healing. Invest Ophthalmol Vis Sci. 1988;29:S307.

    Google Scholar 

  47. Connor T, Roberts AB, Sporn M, et al. Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989;83(5):1661–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science. 1987;237(4820):1333–6.

    Article  CAS  PubMed  Google Scholar 

  49. Sporn MB. Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol. 1987;105:1039–45.

    Article  CAS  PubMed  Google Scholar 

  50. Mukherjee S, Guidry C. The insulin-like growth factor system modulates retinal pigment epithelial cell tractional force generation. Invest Ophthalmol Vis Sci. 2007;48(4):1892–9. https://doi.org/10.1167/iovs.06-1095.

    Article  PubMed  Google Scholar 

  51. Hueber A, Wiedemann P, Esser P, Heimann K. Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR). Int Ophthalmol. 1996;20(6):345–50.

    PubMed  Google Scholar 

  52. Hinton DR, He S, Jin ML, Barron E, Ryan SJ. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (London, England). 2002;16(4):422–8. https://doi.org/10.1038/sj.eye.6700190.

    Article  CAS  Google Scholar 

  53. Abu el-Asrar AM, Van Damme J, Put W, et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol. 1997;123(5):599–606. https://doi.org/10.1016/s0002-9394(14)71072-4.

    Article  PubMed  Google Scholar 

  54. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res. 1995;14(11):1045–53.

    Article  CAS  PubMed  Google Scholar 

  55. Chen Z, Chen CZ, Gong WR, Li JP, Xing YQ. Integrin-alpha5 mediates epidermal growth factor-induced retinal pigment epithelial cell proliferation and migration. Pathobiol J Immunopathol Mol Cell Biol. 2010;77(2):88–95. https://doi.org/10.1159/000278290.

    Article  CAS  Google Scholar 

  56. Armstrong D, Augustin AJ, Spengler R, et al. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. Ophthalmologica. 1998;212(6):410–4. https://doi.org/10.1159/000027378.

    Article  CAS  PubMed  Google Scholar 

  57. Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F, Varinli S. Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm. 2005;13(5):375–81.

    Article  CAS  PubMed  Google Scholar 

  58. Burke J. Cell interactions in proliferative vitreoretinopathy: do growth factors play a role? In: Heimann K, Wiedemann P, editors. Proliferative vitreoretinopathy. Kaden; 1989.

    Google Scholar 

  59. Glaser B. Pathobiology of proliferative vitreoretinopathy. In: Glaser B, Michels R, editors. Surgical Retina. CV Mosby; 1989.

    Google Scholar 

  60. Glaser BM, Cardin A, Biscoe B. Prolieferative vitreoretinopathy: the mechanism of development of vitreoretinal traction. Ophthalmology. 1987;94(4):327–32.

    Article  CAS  PubMed  Google Scholar 

  61. Blumenkranz M, Hartzer M. Contractile mechanisms in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1986;27(suppl):188.

    Google Scholar 

  62. Hiscott P, Grierson I, McLeod D. Retinal pigment epithelial cells in epiretinal membranes: an immunohistochemical study. Br J Ophthalmol. 1984;68(10):708–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Hiscott P, Grierson I, Trombetta C, Rahi A, Marshall J, McLeod D. Retinal and epiretinal glia--an immunohistochemical study. Br J Ophthalmol. 1984;68(10):698–707.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Yamada KM. Cell surface interactions with extracellular materials. Annu Rev Biochem. 1983;52(1):761–99.

    Article  CAS  PubMed  Google Scholar 

  65. Avery RL, Glaser BM. Inhibition of retinal pigment epithelial cell attachment by a synthetic peptide derived from the cell-binding domain of fibronectin. Arch Ophthalmol. 1986;104(8):1220–2.

    Article  CAS  PubMed  Google Scholar 

  66. Campochiaro PA, Jerdan JA, Glaser BM, Cardin A, Michels RG. Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol. 1985;103(9):1403–5.

    Article  CAS  PubMed  Google Scholar 

  67. Csarky K, Hillenius J, Liggett P. Effects of laser and cryotherapy on vitreal fibronectin (FN) concentrations in rabbits. Invest Ophthalmol Vis Sci. 1987;28:209.

    Google Scholar 

  68. Jaccoma EH, Conway BP, Campochiaro PA. Cryotherapy causes extensive breakdown of the blood-retinal barrier: a comparison with argon laser photocoagulation. Arch Ophthalmol. 1985;103(11):1728–30.

    Article  CAS  PubMed  Google Scholar 

  69. Grierson I, Boulton M, Hiscott P, Hitchins C, Gilbert D, McLeod D. Human retinal pigment epithelial cells in the vitreous of the owl monkey. Exp Eye Res. 1986;43(4):491–502.

    Article  CAS  PubMed  Google Scholar 

  70. Morino I, Hiscott P, McKechnie N, Grierson I. Variation in epiretinal membrane components with clinical duration of the proliferative tissue. Br J Ophthalmol. 1990;74(7):393–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Campochiaro PA, Jerdan JA, Glaser BM. Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol. 1984;102(12):1830–3.

    Article  CAS  PubMed  Google Scholar 

  72. Campochiaro PA, Glaser BM. Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol. 1985;103(4):576–9.

    Article  CAS  PubMed  Google Scholar 

  73. Bonnet M. The development of severe proliferative vitreoretinopathy after retinal detachment surgery. Graefes Arch Clin Exp Ophthalmol. 1988;226(3):201–5.

    Article  CAS  PubMed  Google Scholar 

  74. Yoshizumi M, Kreiger A, Sharp D. Risk factors associated with the development of massive periretinal proliferation. Retinal Dis New York: Grune & Stratton. 1985:428–37.

    Google Scholar 

  75. Kirchhof B, Kirchhof E, Sorgente N, Ryan S. Interleukin 1 stimulates migration but not proliferation of pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci. 1987;28:208.

    Google Scholar 

  76. Yu J, Liu F, Cui SJ, et al. Vitreous proteomic analysis of proliferative vitreoretinopathy. Proteomics. 2008;8(17):3667–78. https://doi.org/10.1002/pmic.200700824.

    Article  CAS  PubMed  Google Scholar 

  77. Rojas J, Fernandez I, Pastor JC, et al. Predicting proliferative vitreoretinopathy: temporal and external validation of models based on genetic and clinical variables. Br J Ophthalmol. 2015;99(1):41–8. https://doi.org/10.1136/bjophthalmol-2014-305263.

    Article  PubMed  Google Scholar 

  78. Charteris D, Sethi C, Lewis G, Fisher S. Proliferative vitreoretinopathy—developments in adjunctive treatment and retinal pathology. Eye. 2002;16(4):369.

    Article  CAS  PubMed  Google Scholar 

  79. Eliott D, Stryjewski TP, Andreoli MT, Andreoli CM. Smoking is a risk factor for proliferative vitreoretinopathy after traumatic retinal detachment. Retina. 2017;37(7):1229–35. https://doi.org/10.1097/iae.0000000000001361.

    Article  PubMed  Google Scholar 

  80. Kon CH, Asaria RH, Occleston NL, Khaw PT, Aylward GW. Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study. Br J Ophthalmol. 2000;84(5):506–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Davis J, Jalkh A, Roberge F, et al. Subretinal fluid from human retinal detachment contains interleukin 1. Invest Ophthalmol Vis Sci. 1988;29:396.

    Google Scholar 

  82. Yoshida A, Ho PC, Schepens CL, McMeel JW, Duncan JE. Severe proliferative vitreoretinopathy and retinal detachment: II. Surgical results with scleral buckling. Ophthalmology. 1984;91(12):1538–43.

    Article  CAS  PubMed  Google Scholar 

  83. Bonnet M. Clinical factors predisposing to massive proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Ophthalmologica. 1984;188(3):148–52.

    Article  CAS  PubMed  Google Scholar 

  84. Leaver P. Retinal detachments—when to refer? Identifying the complicated case. Eye. 1989;3(6):754.

    Article  PubMed  Google Scholar 

  85. Asaria RHY, Kon CH, Bunce C, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology. 2001;108(7):1184–6.

    Article  CAS  PubMed  Google Scholar 

  86. Reddy DN, Yonekawa Y, Thomas BJ, Nudleman ED, Williams GA. Long-term surgical outcomes of retinal detachment in patients with Stickler syndrome. Clin Ophthalmol (Auckland, NZ). 2016;10:1531–4. https://doi.org/10.2147/OPTH.S111526.

    Article  CAS  Google Scholar 

  87. McDonald HR, Lewis H, Aaberg TM, Abrams GW. Complications of endodrainage retinotomies created during vitreous surgery for complicated retinal detachment. Ophthalmology. 1989;96(3):358–63.

    Article  CAS  PubMed  Google Scholar 

  88. Abdel-Meguid A, Lappas A, Hartmann K, et al. One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br J Ophthalmol. 2003;87(5):615–21. https://doi.org/10.1136/bjo.87.5.615.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Garcia-Arumi J, Leila M, Zapata MA, et al. Endoresection technique with/without brachytherapy for management of high posterior choroidal melanoma: extended follow-up results. Retina. 2015;35(4):628–37. https://doi.org/10.1097/iae.0000000000000379.

    Article  PubMed  Google Scholar 

  90. Lean JS, Stern WH, Irvine AR, et al. Classification of proliferative vitreoretinopathy used in the silicone study. Ophthalmology. 1989;96(6):765–71.

    Article  CAS  PubMed  Google Scholar 

  91. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112(2):159–65. https://doi.org/10.1016/s0002-9394(14)76695-4.

    Article  CAS  PubMed  Google Scholar 

  92. Di Lauro S, Kadhim MR, Charteris DG, Pastor JC. Classifications for proliferative vitreoretinopathy (PVR): an analysis of their use in publications over the last 15 years. J Ophthalmol. 2016;2016:7807596. https://doi.org/10.1155/2016/7807596.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Moysidis SN, Thanos A, Vavvas DG. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediat Inflamm. 2012;2012

    Google Scholar 

  94. Pastor JC, Rodríguez E, Marcos MA, Lopez M. Combined pharmacologic therapy in a rabbit model of proliferative vitreoretinopathy (PVR). Ophthalmic Res. 2000;32(1):25–9.

    Article  CAS  PubMed  Google Scholar 

  95. Sadaka A, Giuliari GP. Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol (Auckland, NZ). 2012;6:1325.

    Google Scholar 

  96. Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, Mohebbi MR. Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology. 2008;115(11):1938–43.

    Article  PubMed  Google Scholar 

  97. Banerjee PJ, Quartilho A, Bunce C, et al. Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial. Ophthalmology. 2017;124(6):757–67. https://doi.org/10.1016/j.ophtha.2017.01.021.

    Article  PubMed  Google Scholar 

  98. Yamakiri K, Sakamoto T, Noda Y, et al. One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2008;246(7):959–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Gagliano C, Toro MD, Avitabile T, Stella S, Uva MG. Intravitreal steroids for the prevention of PVR after surgery for retinal detachment. Curr Pharm Des. 2015;21(32):4698–702.

    Article  CAS  PubMed  Google Scholar 

  100. Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update. Retina. 2015;35(2):165–75. https://doi.org/10.1097/iae.0000000000000447.

    Article  PubMed  Google Scholar 

  101. Asaria RHY, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108(7):1179–83.

    Article  CAS  PubMed  Google Scholar 

  102. Charteris DG, Aylward GW, Wong D, et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111(12):2240–5.

    Article  PubMed  Google Scholar 

  103. Wiedemann P, Hilgers R, Bauer P, Heimann K, Group DS. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Am J Ophthalmol. 1998;126(4):550–9.

    Article  CAS  PubMed  Google Scholar 

  104. Chang Y-C, Hu D-N, Wu W-C. Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy. Am J Ophthalmol. 2008;146(3):440–446. e1.

    Article  CAS  PubMed  Google Scholar 

  105. Lemor M, de Bustros S, Glaser BM. Low-dose colchicine inhibits astrocyte, fibroblast, and retinal pigment epithelial cell migration and proliferation. Arch Ophthalmol. 1986;104(8):1223–5.

    Article  CAS  PubMed  Google Scholar 

  106. Mandava N, Blackburn P, Paul DB, et al. Ribozyme to proliferating cell nuclear antigen to treat proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2002;43(10):3338–48.

    PubMed  Google Scholar 

  107. Schiff WM, Hwang JC, Ober MD, et al. Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol. 2007;125(9):1161–7.

    Article  CAS  PubMed  Google Scholar 

  108. Wickham L, Bunce C, Wong D, McGurn D, Charteris D. Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. 2007;114(4):698–704.

    Article  CAS  PubMed  Google Scholar 

  109. Amarnani D, Machuca-Parra AI, Wong LL, et al. Effect of methotrexate on an in vitro patient-derived model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2017;58(10):3940–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Hardwig PW, Pulido JS, Bakri SJ. The safety of intraocular methotrexate in silicone-filled eyes. Retina. 2008;28(8):1082–6.

    Article  PubMed  Google Scholar 

  111. Sadaka A, Sisk RA, Osher JM, Toygar O, Duncan MK, Riemann CD. Intravitreal methotrexate infusion for proliferative vitreoretinopathy. Clin Ophthalmol (Auckland, NZ). 2016;10:1811.

    Article  CAS  Google Scholar 

  112. Benner JD, Dao D, Butler JW, Hamill KI. Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy. BMJ Open Ophthalmol. 2019;4(1):e000293. https://doi.org/10.1136/bmjophth-2019-000293.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Zheng Y, Ikuno Y, Ohj M, et al. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol. 2003;47(2):158–65.

    Article  CAS  PubMed  Google Scholar 

  114. Liang CM, Tai MC, Chang YH, et al. Glucosamine inhibits epithelial-to-mesenchymal transition and migration of retinal pigment epithelium cells in culture and morphologic changes in a mouse model of proliferative vitreoretinopathy. Acta Ophthalmol. 2011;89(6):e505–14.

    Article  PubMed  Google Scholar 

  115. Lei H, Velez G, Cui J, et al. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol. 2010;177(1):132–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Alex AF, Spitznas M, Tittel AP, Kurts C, Eter N. Inhibitory effect of epigallocatechin gallate (EGCG), resveratrol, and curcumin on proliferation of human retinal pigment epithelial cells in vitro. Curr Eye Res. 2010;35(11):1021–33.

    Article  CAS  PubMed  Google Scholar 

  117. Al T, Schuettauf F, Monnier PP, Bartz-Schmidt KU, Henke-Fahle S. Efficacy of rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Invest Ophthalmol Vis Sci. 2009;50(1):452–61.

    Article  Google Scholar 

  118. Lewis GP, Chapin EA, Byun J, Luna G, Sherris D, Fisher SK. Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. Invest Ophthalmol Vis Sci. 2009;50(9):4429–35.

    Article  PubMed  Google Scholar 

  119. Koerner F, Koerner-Stiefbold U, Garweg JG. Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2012;250(7):981–7. https://doi.org/10.1007/s00417-011-1919-y.

    Article  CAS  PubMed  Google Scholar 

  120. Bonfiglio V, Reibaldi M, Macchi I, et al. Preoperative, intraoperative and postoperative corticosteroid use as an adjunctive treatment for Rhegmatogenous retinal detachment. J Clin Med. 2020;9(5) https://doi.org/10.3390/jcm9051556.

  121. van Bockxmeer FM, Martin CE, Thompson DE, Constable IJ. Taxol for the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1985;26(8):1140–7.

    PubMed  Google Scholar 

  122. Fekrat S, de Juan E, Jr., Campochiaro PA. The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy. Ophthalmology. 1995;102(3):412–8. https://doi.org/10.1016/s0161-6420(95)31007-x.

    Article  CAS  PubMed  Google Scholar 

  123. Ghasemi Falavarjani K, Hashemi M, Modarres M, Hadavand KA. Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. Eye (London, England). 2014;28(5):576–80. https://doi.org/10.1038/eye.2014.21.

    Article  CAS  Google Scholar 

  124. Hsu J, Khan MA, Shieh WS, et al. Effect of serial intrasilicone oil bevacizumab injections in eyes with recurrent proliferative vitreoretinopathy retinal detachment. Am J Ophthalmol. 2016;161:65–70.e1-2. https://doi.org/10.1016/j.ajo.2015.09.029.

    Article  CAS  PubMed  Google Scholar 

  125. Lei H, Velez G, Cui J, et al. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol. 2010;177(1):132–40. https://doi.org/10.2353/ajpath.2010.090604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Coffee RE, Jiang L, Rahman SA. Proliferative vitreoretinopathy: advances in surgical management. Int Ophthalmol Clin. 2014;54(2):91–109. https://doi.org/10.1097/iio.0000000000000023.

    Article  PubMed  Google Scholar 

  127. Grizzard WS, Hilton GF. Scleral buckling for retinal detachments complicated by periretinal proliferation. Arch Ophthalmol. 1982;100(3):419–22.

    Article  CAS  PubMed  Google Scholar 

  128. Storey P, Alshareef R, Khuthaila M, et al. Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy. Retina. 2014;34(10):1945–51. https://doi.org/10.1097/iae.0000000000000216.

    Article  PubMed  Google Scholar 

  129. Erakgun T, Egrilmez S. Surgical outcomes of transconjunctival sutureless 23-gauge vitrectomy with silicone oil injection. Indian J Ophthalmol. 2009;57(2):105–9. https://doi.org/10.4103/0301-4738.44514.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Iwahashi-Shima C, Sato T, Bando H, Ikeda T, Emi K. Anatomic and functional outcomes of 25-gauge vitrectomy for repair of eyes with rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy. Clin Ophthalmol (Auckland, NZ). 2013;7:2043–9. https://doi.org/10.2147/opth.S52260.

    Article  Google Scholar 

  131. Khan MA, Kuley A, Riemann CD, et al. Long-term visual outcomes and safety profile of 27-gauge pars Plana vitrectomy for posterior segment disease. Ophthalmology. 2018;125(3):423–31. https://doi.org/10.1016/j.ophtha.2017.09.013.

    Article  PubMed  Google Scholar 

  132. Sato T, Emi K, Bando H, Ikeda T. Retrospective comparison of 25-gauge vitrectomy for repair of proliferative vitreoretinopathy with or without anterior proliferation. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2014;252(12):1895–902. https://doi.org/10.1007/s00417-014-2846-5.

    Article  CAS  PubMed  Google Scholar 

  133. Parke DW, Aaberg TM. Intraocular argon laser photocoagulation in the management of severe proliferative vitreoretinopathy. Am J Ophthalmol. 1984;97(4):434–43.

    Article  PubMed  Google Scholar 

  134. Chang S, Coleman DJ, Lincoff H, Wilcox LM Jr, Maisel JM, Braunstein R. Perfluoropropane gas in the management of proliferative vitreoretinopathy. Am J Ophthalmol. 1984;98(2):180–8.

    Article  CAS  PubMed  Google Scholar 

  135. Blumenkranz M, Gardner T, Blankenship G. Fluid-gas exchange and photocoagulation after vitrectomy: indications, technique, and results. Arch Ophthalmol. 1986;104(2):291–6.

    Article  CAS  PubMed  Google Scholar 

  136. Aaberg T. Management of anterior and posterior proliferative vitreoretinopathy XLV Edward Jackson memorial lecture. Am J Ophthalmol. 1988;106(5):519–32.

    Article  CAS  PubMed  Google Scholar 

  137. Lewis H, Aaberg TM. Anterior proliferative vitreoretinopathy. Am J Ophthalmol. 1988;105(3):277–84.

    Article  CAS  PubMed  Google Scholar 

  138. Hanneken AM, Michels RG. Vitrectomy and scleral buckling methods for proliferative vitreoretinopathy. Ophthalmology. 1988;95(7):865–9.

    Article  CAS  PubMed  Google Scholar 

  139. De JJE. Management of anterior vitreous traction in proliferative vitreoretinopathy. Retina (Philadelphia, Pa). 1989;9(4):258–62.

    Article  Google Scholar 

  140. Lewis H, Aaberg TM. Causes of failure after repeat vitreoretinal surgery for recurrent proliferative vitreoretinopathy. Am J Ophthalmol 1991;111(1):15–19.

    Google Scholar 

  141. Lewis H, Aaberg TM, Abrams GW. Causes of failure after initial vitreoretinal surgery for severe proliferative vitreoretinopathy. Am J Ophthalmol. 1991;111(1):8–14.

    Article  CAS  PubMed  Google Scholar 

  142. Ajlan RS, Desai AA, Mainster MA. Endoscopic vitreoretinal surgery: principles, applications and new directions. Int J Retina Vitreous. 2019;5:15. https://doi.org/10.1186/s40942-019-0165-z.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Boscher C, Kuhn F. An endoscopic overview of the anterior vitreous base in retinal detachment and anterior proliferative vitreoretinopathy. Acta Ophthalmol. 2014;92(4):e298–304. https://doi.org/10.1111/aos.12303.

    Article  PubMed  Google Scholar 

  144. Garnier S, Rahmi A, Grasswil C, Kodjikian L. Three hundred and sixty degree retinotomy for retinal detachments with severe proliferative vitreoretinopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2013;251(9):2081–5. https://doi.org/10.1007/s00417-013-2298-3.

    Article  PubMed  Google Scholar 

  145. Abu Eleinen KG, Mohalhal AA, Ghalwash DA, et al. Vitrectomy with scleral buckling versus with inferior retinectomy in treating primary rhegmatogenous retinal detachment with PVR and inferior breaks. Eye (London, England). 2018;32(12):1839–44. https://doi.org/10.1038/s41433-018-0194-0.

    Article  Google Scholar 

  146. Mancino R, Aiello F, Ciuffoletti E, Di Carlo E, Cerulli A, Nucci C. Inferior retinotomy and silicone oil tamponade for recurrent inferior retinal detachment and grade C PVR in eyes previously treated with pars plana vitrectomy or scleral buckle. BMC Ophthalmol. 2015;15:173. https://doi.org/10.1186/s12886-015-0167-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Mendes TS, Gomes AMV, Rocha BS, Passos Junior HV, Abujamra S. Evaluation of retinectomy in the treatment of severe proliferative vitreoretinopathy. Int J Retina Vitreous. 2015;1:17. https://doi.org/10.1186/s40942-015-0018-3.

    Article  PubMed  PubMed Central  Google Scholar 

  148. Han DP, Lewis MT, Kuhn EM, et al. Relaxing retinotomies and retinectomies: surgical results and predictors of visual outcome. Arch Ophthalmol. 1990;108(5):694–7.

    Article  CAS  PubMed  Google Scholar 

  149. GARCIA-VALENZUELA E, ITO Y, ABRAMS GW. Risk factors for retention of subretinal perfluorocarbon liquid in vitreoretinal surgery. Retina. 2004;24(5):746–52.

    Article  PubMed  Google Scholar 

  150. Akiyama K, Fujinami K, Watanabe K, Tsunoda K, Noda T. Internal limiting membrane peeling to prevent post-vitrectomy Epiretinal membrane development in retinal detachment. Am J Ophthalmol. 2016;171:1–10. https://doi.org/10.1016/j.ajo.2016.08.015.

    Article  PubMed  Google Scholar 

  151. Rao RC, Blinder KJ, Smith BT, Shah GK. Internal limiting membrane peeling for primary rhegmatogenous retinal detachment repair. Ophthalmology. 2013;120(5):1102-3.e1-2. https://doi.org/10.1016/j.ophtha.2012.12.010.

    Article  PubMed  Google Scholar 

  152. Yannuzzi NA, Callaway NF, Sridhar J, Smiddy WE. Internal limiting membrane peeling during pars plana vitrectomy for rhegmatogenous retinal detachment: cost analysis, review of the literature, and meta-analysis. Retina. 2018;38(10):2081–7. https://doi.org/10.1097/iae.0000000000002248.

    Article  PubMed  Google Scholar 

  153. Bracha P, Ciulla TA, Baumal CR. Vital dyes in vitreomacular surgery. Ophthal Surgery Lasers Imag Retina. 2018;49(10):788–98. https://doi.org/10.3928/23258160-20181002-07.

    Article  Google Scholar 

  154. Tognetto D, De Giacinto C, D'Aloisio R, Papagno C, Pastore M, Zweyer M. The combination of trypan blue and brilliant blue G-assisted vitrectomy for macular pucker: histopathological findings. Ophthalmologica. 2018;239(2–3):167–75. https://doi.org/10.1159/000485986.

    Article  CAS  PubMed  Google Scholar 

  155. Minarcik JR, von Fricken MA. Virtual retinectomy: indocyanine green-assisted internal limiting membrane peeling as a surgical adjunct in repair of recurrent rhegmatogenous retinal detachment due to PVR. Clin Ophthalmol (Auckland, NZ). 2012;6:631–6. https://doi.org/10.2147/opth.S29654.

    Article  Google Scholar 

  156. Chang S, Ozmert E, Zimmerman NJ. Intraoperative perfluorocarbon liquids in the management of proliferative vitreoretinopathy. Am J Ophthalmol. 1988;106(6):668–74.

    Article  CAS  PubMed  Google Scholar 

  157. Coll GE, Chang S, Sun J, Wieland MR, Berrocal MH. Perfluorocarbon liquid in the management of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1995;102(4):630–8. discussion 638-9

    Article  CAS  PubMed  Google Scholar 

  158. Roth DB, Sears JE, Lewis H. Removal of retained subfoveal perfluoro-n-octane liquid. Am J Ophthalmol. 2004;138(2):287–9.

    Article  PubMed  Google Scholar 

  159. Kontos A, Tee J, Stuart A, Shalchi Z, Williamson TH. Duration of intraocular gases following vitreoretinal surgery. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2017;255(2):231–6. https://doi.org/10.1007/s00417-016-3438-3.

    Article  PubMed  Google Scholar 

  160. Keilani C, Augstburger E, Robin M, et al. Comparative biochemical outcomes, effectiveness and tolerance of Densiron 68 and Oxane HD for the management of complicated retinal detachment. Turk J Ophthalmol. 2019;49(6):334–41. https://doi.org/10.4274/tjo.galenos.2019.24294.

    Article  PubMed  PubMed Central  Google Scholar 

  161. Caporossi T, Tartaro R, Finocchio L, et al. Perfluorodecalin versus Densiron 68 heavy silicone oil in the management of inferior retinal detachment recurrence. Ophthal Surg Laser Imag Retina. 2019;50(5):274–80. https://doi.org/10.3928/23258160-20190503-03.

    Article  Google Scholar 

  162. Group SOS. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: result of a randomized clinical trial, silicone study report 2. Arch Ophthalmol. 1992;110:780–92.

    Article  Google Scholar 

  163. Barr CC, Lai MY, Lean JS, et al. Postoperative intraocular pressure abnormalities in the silicone study: silicone study report 4. Ophthalmology. 1993;100(11):1629–35.

    Article  CAS  PubMed  Google Scholar 

  164. Blumenkranz M, Azen S, Aaberg T, et al. Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy silicone study report 5. Am J Ophthalmol. 1993;116(5):557–64.

    Article  CAS  PubMed  Google Scholar 

  165. Abrams GW, Azen SP, McCuen BW, Flynn HW, Lai MY, Ryan SJ. Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up: silicone study report 11. Arch Ophthalmol. 1997;115(3):335–44.

    Article  CAS  PubMed  Google Scholar 

  166. Refojo M, Chung H, Ueno N, et al. Solubility of retinol in intraocular silicone oil. Invest Ophthalmol Vis Sci. 1987;210(28)

    Google Scholar 

  167. Gonvers M, Hornung J-P, de Courten C. The effect of liquid silicone on the rabbit retina: histologic and ultrastructural study. Arch Ophthalmol. 1986;104(7):1057–62.

    Article  CAS  PubMed  Google Scholar 

  168. Gray R, Cringle S, Constable I. Fluorescein angiographic findings in three patients with long-term intravitreal liquid silicone. Br J Ophthalmol. 1989;73(12):991–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Boren RA, Cloy CD, Gupta AS, Dewan VN, Hogan RN. Retrolaminar migration of intraocular silicone oil. J Neuroophthalmol. 2016;36(4):439–47. https://doi.org/10.1097/WNO.0000000000000440.

    Article  PubMed  Google Scholar 

  170. Abdalkader M, Takumi K, Chapman MN, Barest GD, Peeler C, Sakai O. Subretinal and retrolaminar migration of intraocular silicone oil detected on CT. AJNR Am J Neuroradiol. 2019;40(9):1557–61. https://doi.org/10.3174/ajnr.A6176.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Mrejen S, Sato T, Fisher Y, Spaide RF. Intraretinal and intra-optic nerve head silicone oil vacuoles using adaptive optics. Ophthalmic Surg Lasers Imaging Retina. 2014;45(1):71–3. https://doi.org/10.3928/23258160-20131220-11.

    Article  PubMed  Google Scholar 

  172. Lean J, Boone D, Azen S, et al. Silicone study group: vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy. Results of a randomized clinical trial (Silicone study report no. 1). Arch Ophthalmol. 1992;110:770–9.

    Article  Google Scholar 

  173. Kiss CG, Richter-Muksch S, Sacu S, Benesch T, Velikay-Parel M. Anatomy and function of the macula after surgery for retinal detachment complicated by proliferative vitreoretinopathy. Am J Ophthalmol. 2007;144(6):872–7. https://doi.org/10.1016/j.ajo.2007.08.001.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The author acknowledges Dr. John S Lean and Dr. Dennis P. Han, for their contributions to the original and previously published versions of this chapter.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Duke University, Durham, NC, USA

    Wenlan Zhang, Lejla Vajzovic & Cynthia A. Toth

  2. Department of Biomedical Engineering, Duke University, Durham, NC, USA

    Cynthia A. Toth

Authors
  1. Wenlan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lejla Vajzovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cynthia A. Toth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cynthia A. Toth .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, Oregon Health & Science University Department of Ophthalmology, Portland, OR, USA

    Daniel Albert

  2. Massachusetts Eye and Ear, Boston, MA, USA

    Joan Miller

  3. Department of Ophthalmology, University of Illinois at Chicago Department of Ophthalmology, Chicago, IL, USA

    Dimitri Azar

  4. Department of Ophthalmology, Harvard Medical School, Boston, MA, USA

    Lucy H. Young

Section Editor information

  1. Massachusetts Eye and Ear, Boston, USA

    Dean Eliott

  2. Massachusetts Eye and Ear, Boston, USA

    Demetrios Vavvas

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Zhang, W., Vajzovic, L., Toth, C.A. (2021). Proliferative Vitreoretinopathy. In: Albert, D., Miller, J., Azar, D., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-319-90495-5_97-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90495-5_97-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90495-5

  • Online ISBN: 978-3-319-90495-5

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation